Background and Study Aims: The prevalence of esophageal squamous-cell carcinoma in high-risk patients and the advantages of systematic Lugol staining during esophagoscopy have not yet been evaluated in a large prospective study. In this study we aimed to assess the prevalence of this type of tumor in high-risk patients, to examine the role of Lugol staining in endoscopic screening for esophageal squamous-cell carcinoma, and to establish whether it is possible to identify a particularly high-risk group which would benefit from systematic screening.
Patients and Methods: A prospective study was undertaken in 62 endoscopy centers. A total of 1095 patients were enrolled, none of whom had any esophageal symptoms. These patients had presented with either a past history of or a recent head and neck or tracheobronchial squamous-cell carcinoma (group 1), with alcoholic chronic pancreatitis (group 2), with alcoholic cirrhosis (group 3), or were alcohol and tobacco addicts (group 4). The patients underwent a meticulous endoscopic examination of the esophagus, followed by Lugol staining.
Results: The prevalence of esophageal squamous-cell carcinoma was 3.2 %. The group 1 patients showed the highest prevalence of carcinoma (5.3 %) and the highest prevalence of dysplasia (4.5 %). Of the 35 carcinomas detected in the 1095 patients, seven (20 %) were early lesions, and 20 % were only detected after Lugol staining (P = 0.02). High-grade dysplasia was only observed in group 1 patients and two-thirds of these lesions were only diagnosed after Lugol staining. The overall prevalence of low-grade dysplasia was 2.4 %, and 77 % of these were detected only after Lugol staining (P < 0.001).
Conclusions: Lugol dye staining increases the sensitivity of esophageal endoscopy for the detection of high-grade dysplasia and cancer. The prevalence of dysplasia and cancer reached 9.9 % in group 1, and we therefore believe that an endoscopic screening program could be justified for patients with head and neck or tracheobronchial cancer.
References
1
Blot W J.
Esophageal cancer trends and risk factors.
Semin Oncol.
1994;
21
403-410
2
Remontet L, Esteve J, Bouvier A M. et al .
Cancer incidence and mortality in France over the period 1978 - 2000.
Rev Epidemiol Sante Publique.
2003;
51
3-30
3
Holscher A H, Bollschweiler E, Schneider P M, Siewert J R.
Prognosis of early esophageal cancer: comparison between adeno- and squamous cell carcinoma.
Cancer.
1995;
76
178-186
4
Nabeya K, Hanaoka T, Li S, Nyumura T.
What is the ideal treatment for early esophageal cancer?.
Endoscopy.
1993;
25
670-671
5
Froelicher P, Miller G.
The European experience with esophageal cancer limited to the mucosa and submucosa.
Gastrointest Endosc.
1986;
32
88-90
6
The Research Group for Population-Based Cancer Registration in Japan .
Cancer incidence in Japan 1985 - 89: re-estimation based on data from eight population-based cancer registries.
Jpn J Clin Oncol.
1998;
28
54-67
7
Inoue H, Rey J F, Lightdale C.
Lugol chromoendoscopy for esophageal squamous cell cancer.
Endoscopy.
2001;
33
75-79
8
Ponchon T.
Endoscopic diagnosis of superficial neoplastic lesions of the digestive tract.
Gastroenterol Clin Biol.
2000;
24
B109-B122
9
Meyer V, Burtin P, Bour B. et al .
Endoscopic detection of early esophageal cancer in a high-risk population: does Lugol staining improve videoendoscopy?.
Gastrointest Endosc.
1997;
45
480-484
10
Nothmann B J, Wright J R, Schuster M M.
In vivo vital staining as an aid to identification of the esophagogastric mucosal junction in man.
Am J Dig Dis.
1972;
17
919-924
11
Pichon N, Vincensini J F, Debette-Gratien M. et al .
Interest of chemoendoscopy with lugol in early diagnosis of malignant lesions of the oesophagus (abstract).
Gastroenterol Clin Biol.
2002;
26
168
12
Yokoyama A, Ohmori T, Makuuchi H. et al .
Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining.
Cancer.
1995;
76
928-934
13
Ban S, Toyonaga A, Harada H. et al .
Iodine staining for early endoscopic detection of esophageal cancer in alcoholics.
Endoscopy.
1998;
30
253-257
14
Fagundes R B, de Barros S G, Putten A C. et al .
Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics at high risk for squamous cell carcinoma of the esophagus.
Endoscopy.
1999;
31
281-285
15
Makuuchi H, Machimura T, Shimada H. et al .
Endoscopic screening for esophageal cancer in 788 patients with head and neck cancers.
Tokai J Exp Clin Med.
1996;
21
139-145
16
Papazian A, Descombes P, Capron J P, Lorriaux A.
Incidence of esophageal cancer synchronous with upper aerodigestive tract cancers (100 cases): value of vital staining with lugol and toluidine blue.
Gastroenterol Clin Biol.
1985;
9
16-22
17
Launoy G, Milan C H, Faivre J. et al .
Alcohol, tobacco and esophageal cancer: effects of the duration of consumption, mean intake and current and former consumption.
Br J Cancer.
1997;
75
1389-1396
18
Tuyns A J, Sasco A J.
Incidence of tobacco and alcohol-related cancers in western Europe.
Eur J Cancer Prev.
1997;
6
560-561
19
Bogomoletz W V, Molas G, Gayet B, Potet F.
Superficial squamous cell carcinoma of the esophagus: a report of 76 cases and review of the literature.
Am J Surg Pathol.
1989;
13
535-546
20
Kato H, Tachimori Y, Watanabe H. et al .
Superficial esophageal carcinoma: surgical treatment and the results.
Cancer.
1990;
66
2319-2323
21
Fujii T, Yamana H, Fujita H. et al .
Clinicopathologic study of multiple primary superficial carcinoma of the esophagus.
Int J Oncol.
1998;
12
421-425
22
Liu H H, Yoshida M, Momma K. et al .
Detection and treatment of an asymptomatic case of early esophageal cancer using chromoendoscopy and endoscopic mucosal resection.
J Formos Med Assoc.
2002;
101
219-222
23
May A, Gossner L, Behrens A. et al .
A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus.
Gastrointest Endosc.
2003;
58
167-175
24
Soetikno R M, Gotoda T, Nakanishi Y, Soehendra N.
Endoscopic mucosal resection.
Gastrointest Endosc.
2003;
57
567-579
J.-L. Legoux, M. D.
Hepatogastroenterology Department
Haut Leveque Hospital · Bordeaux University Hospital · 33604 Pessac · France
Fax: +33-557656445
eMail: Jean-louis.legoux@chu-bordeaux.fr